Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PDSB PDS Biotechnology Corp
- Stocks
- Healthcare
- NASDAQ: PDSB
Price (delayed)
$1.65
Market cap
$75.42M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.94
Enterprise value
$54.4M
PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively
Highlights
PDS Biotechnology's EPS has increased by 31% YoY and by 9% QoQ
PDS Biotechnology's debt has decreased by 21% YoY and by 13% QoQ
The equity has contracted by 40% YoY but it has grown by 18% from the previous quarter
The quick ratio has plunged by 50% YoY and by 10% from the previous quarter
Key stats
What are the main financial stats of PDSB
Market
Valuations
Earnings
Shares outstanding
45.71M
Market cap
$75.42M
Enterprise value
$54.4M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.35
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$35.33M
Net income
-$35.5M
EBIT
-$35.33M
EBITDA
-$35.31M
Free cash flow
-$34.12M
Per share
Balance sheet
Liquidity
EPS
-$0.94
EPS diluted
-$0.94
Free cash flow per share
-$0.84
Book value per share
$0.49
Revenue per share
$0
TBVPS
$1.16
Total assets
$47.03M
Total liabilities
$24.67M
Debt
$18.96M
Equity
$22.36M
Working capital
$24.2M
Debt to equity
0.85
Current ratio
2.33
Quick ratio
2.19
Net debt/EBITDA
0.6
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-69.1%
Return on equity
-150.6%
Return on invested capital
-385.6%
Return on capital employed
-122.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PDSB stock price
How has the PDS Biotechnology stock price performed over time
Intraday
7.84%
1 week
20.44%
1 month
19.57%
1 year
-43.1%
YTD
1.23%
QTD
38.66%
Financial performance
How have PDS Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$35.33M
Net income
-$35.5M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 19% YoY and by 2.7% from the previous quarter
PDS Biotechnology's net income has increased by 19% YoY and by 6% from the previous quarter
Price vs fundamentals
How does PDSB's price correlate with its fundamentals
Growth
What is PDS Biotechnology's growth rate over time
Valuation
What is PDS Biotechnology stock price valuation
P/E
N/A
P/B
3.35
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
PDS Biotechnology's EPS has increased by 31% YoY and by 9% QoQ
The equity has contracted by 40% YoY but it has grown by 18% from the previous quarter
The P/B is 16% lower than the 5-year quarterly average of 4.0 and 14% lower than the last 4 quarters average of 3.9
Efficiency
How efficient is PDS Biotechnology business performance
PDS Biotechnology's ROIC has decreased by 34% YoY and by 7% from the previous quarter
PDSB's ROE is down by 9% QoQ and by 3.2% YoY
The ROA is down by 4.4% QoQ
Dividends
What is PDSB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PDSB.
Financial health
How did PDS Biotechnology financials performed over time
PDS Biotechnology's total assets is 91% more than its total liabilities
The quick ratio has plunged by 50% YoY and by 10% from the previous quarter
PDSB's current ratio is down by 49% year-on-year and by 12% since the previous quarter
PDS Biotechnology's debt is 15% lower than its equity
The equity has contracted by 40% YoY but it has grown by 18% from the previous quarter
The debt to equity is up by 31% year-on-year but it has declined by 26% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.